

CNMV  
Edison, 4  
28006 Madrid

Barcelona (Spain), May 3, 2017

## RELEVANT FACT

Dear Sir,

In accordance with the Article 228 of Royal Legislative Decree 4/2015, dated 23 October, which enacts the consolidated text of the Securities Market Act, LABORATORIO REIG JOFRE SA ("Reig Jofre" or "the Company") submits hereafter press release on the participation of Reig Jofre in the first recombinant veterinary vaccine against Leishmaniasis, by Laboratorios LETI

Adolf Rousaud  
Secretary of the Board of Directors  
Laboratorio Reig Jofre SA

## REIG JOFRE, STRATEGIC PARTNER IN THE STABILIZATION AND PRODUCTION OF THE FIRST RECOMBINANT VETERINARY VACCINE AGAINST LEISHMANIASIS, BY LABORATORIOS LETI

- Reig Jofre has collaborated over the past seven years with Laboratorios LETI in the industrial development of the first recombinant veterinary vaccine against leishmaniasis, a biotechnological active for which stabilization processes are highly complex.
- From now on, Reig Jofre will produce for Laboratorios LETI this biotech vaccine developed from protein Q, which Laboratorios LETI plans to commercialize internationally.

**Barcelona, May 3, 2017.** The pharmaceutical company Reig Jofre has collaborated closely in the industrial development of the first recombinant veterinary vaccine against canine leishmaniasis, owned by Laboratorios LETI and developed from protein Q. This vaccine has been fully developed in Spain, where it is already being commercialized.

In addition, Laboratorios LETI plans to market this vaccine also internationally, for which it has already obtained authorization from the European Medicines Agency for all its member states.

This biotechnological development is the result of Laboratorios LETI's research over twenty years, to which Reig Jofre has contributed over the past seven years with its knowledge in the analysis, stabilization and production of biotech injectable products.

Following the conclusion of the development phase, Reig Jofre is producing for Laboratorios LETI this biotechnological vaccine at its specialized plant in injectable products located in Barcelona.

Leishmaniasis is a serious, potentially lethal disease caused by the parasite *Leishmania infantum*, prevalent in the Mediterranean area. The infected dog, in addition to being able to suffer the disease, is the main reservoir from where this parasite is transmitted to other dogs and people by the bite of the mosquito phlebotomus, which acts as a vector.



Reig Jofre's injectable products unit is a strategic pillar for the company. With nearly four decades of experience, it has a center of excellence dedicated to the study of the lyophilization processes, stabilization of complex molecules, proteins, peptides or biological, and it also has a laboratory with capacity for analytical development associated to the processes of lyophilization and quality control.

The capability to carry out a development from the research phase to industrialization, as it is the case of this biotech vaccine developed from protein Q, makes Reig Jofre the strategic partner for many pharmaceutical companies and national and international start-ups, who need to take their most innovative products to the clinical stages and to the market.

Reig Jofre is actively investing to expand the capacity of the injectable unit, which is progressing very significantly in international markets.

Get timely updates of Reig Jofre news by registering in the company's **subscription centre** on the corporate website: **[www.reigjofre.com](http://www.reigjofre.com)**

### **About Reig Jofre**

Founded in Barcelona in 1929, Reig Jofre is a multinational pharmaceutical company with activity structured around two major axes: the main one, own-product manufacture and marketing (RJF Pharma, 80% of total sales) and a complementary one, development and manufacture for third parties (RJF CDMO, 20% of total sales). In its main activity, the company focuses on developing specialised technological products (antibiotics and solutions for injection); specialised therapeutic products for the dermatology, gynaecology and respiratory fields; and dietary supplements and consumer healthcare. The company focuses its R+D activity on developing new indications and/or pharmaceutical forms using known active substances, generic medicines with a particular focus on beta-lactam antibiotics and solutions for injection, topical dermatological products, OTCs and dietary supplements, and in addition develops new innovative molecules in partnership with start-ups and research centres.

Reig Jofre has over 900 employees, 4 development centres and 3 production centres in Europe, direct sales in 6 European countries and over 130 business partners in 63 countries across the world. The company closed 2016 with a turnover of 161 million euros.

Reig Jofre is listed on the Spanish Stock Exchange under the ticker RJF. Reig Jofre is listed on the Spanish Stock Exchange under the ticker RJF. Share capital: 63,214,220 shares.

### **For further information:**

---

#### **Investors and analysts**



Gloria Folch  
Tel. (+34) 93 480 67 10 – ext. 1241  
gloria.folch@reigjofre.com

**Media**

Inma Santa-Pau  
Tel. (+34) 93 480 67 10 – ext. 1242  
inma.santapau@reigjofre.com